U.S. FDA puts partial hold on Blueprint Medicines cancer drug trial (updated)

Blueprint Medicines

10/02/2023 13:39

(Adds details)
       Feb 10 (Reuters) - Blueprint Medicines Corp  BPMC.O 
said on Friday the U.S. drug regulator had put on partial hold
an early-stage trial of its experimental cancer drug due to
safety concerns.
    Some patients faced episodes of light sensitivity and
blurred vision, the drug developer said. 
    Patients with advanced solid tumors currently enrolled in
the trial will continue on the drug, the company said, while
additional enrollments will be paused until the partial clinical
hold is resolved. 
    Shares of the company were down 7.11% in premarket trading
at $41.14
 (Reporting by Pratik Jain in Bengaluru; Editing by Dhanya Ann
Thoppil and Sriraj Kalluvila)
 ((Pratik.Jain@thomsonreuters.com;))